Mesoblast Limited announced that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). Mesoblast intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.025 AUD | -3.76% | -16.67% | +230.65% |
May. 01 | Mesoblast Limited Announces Board and Committee Changes | CI |
Apr. 01 | ADRs End Higher; Connect Biopharma Climbs 26% | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+230.65% | 807M | |
+55.25% | 59.34B | |
+43.17% | 40.24B | |
-5.07% | 39.88B | |
-5.56% | 28.55B | |
+14.95% | 27.26B | |
-21.67% | 19.23B | |
+31.53% | 12.61B | |
+2.18% | 12.49B | |
+25.78% | 12.28B |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease